Methotrexate versus ciclosporin in the treatment of severe atopic eczema in children: an economic evaluation
Ciclosporin (CsA) and methotrexate (MTX) are both frequently prescribed drugs for the treatment of atopic dermatitis (AD) in children and young people. Historically, CsA has been the most commonly used conventional systemic treatment for severe paediatric AD, but MTX is being increasingly used as an alternative first-line conventional systemic treatment, especially in middle- and low-income settings. We found that MTX provides an effective and low-cost first-line systemic treatment for severe AD and is a suitable alternative to CsA.
Authors
- Ashley P Jones (ORCID: https://orcid.org/0000-0001-5253-730X)
- Anna Rosala‐Hallas (ORCID: https://orcid.org/0000-0001-8012-9995)
- Catherine Spowart (ORCID: https://orcid.org/0000-0001-8641-2871)
- Mandy Wan (ORCID: https://orcid.org/0000-0001-8802-0425)
- Farhiya Ashoor
- Tracey Sach (ORCID: https://orcid.org/0000-0002-8098-9220)
- Carsten Flohr (ORCID: https://orcid.org/0000-0003-4884-6286)
- Fiona Browne (ORCID: https://orcid.org/0000-0002-0194-480X)
- Susannah Baron (ORCID: https://orcid.org/0000-0003-2639-7854)
- Alan D. Irvine (ORCID: https://orcid.org/0000-0002-9048-2044)
- Amina Ahmed (ORCID: https://orcid.org/0000-0002-4016-4363)
- Paula Beattie (ORCID: https://orcid.org/0009-0009-5205-0572)
- Kaitlyn R Chan
Institutions
- University of East Anglia (GB)
- University of Liverpool (GB)
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Trinity College Dublin (IE)
- NHS Greater Glasgow and Clyde (GB)
- Royal Hospital for Children (GB)
- House of Representatives (NL)
- Our Lady's Hospital (IE)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1093/bjd/ljae363
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health and Care Research
- Centro Singular de Investigación de Galicia
- Medical Research Council
- Efficacy and Mechanism Evaluation Programme
- Research for Patient Benefit Programme